Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis
Riaz I, Fuentes H, Naqvi S, He H, Sipra Q, Tafur A, Padranos L, Wysokinski W, Marshall A, Vandvik P, Montori V, Bryce A, Liu H, Badgett R, Murad M, McBane R. Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis. Mayo Clinic Proceedings 2021, 97: 308-324. PMID: 34172290, DOI: 10.1016/j.mayocp.2020.10.041.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsCancer-associated thrombosisTreatment of CATMajor bleedingSystematic reviewOral anticoagulantsRecurrent venous thromboembolism (VTE) eventsRelevant nonmajor bleedingUse of apixabanVenous thromboembolism eventsNetwork Meta-AnalysisStandard of careDifferent treatment optionsMixed treatment comparisonNonmajor bleedingThromboembolism eventsVTE recurrenceControlled TrialsWeight heparinTreatment optionsDalteparinHigh riskCurrent evidenceBleedingMeta-Analysis